Loading…
Loading…
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its third quarter 2026 investor conference call at 4:30 p.m. ET on Wednesday, November 4, 2026. Warrior will release its results following the close of market trading that afternoon. To participate in the conference call, please call 1-844-340-9047 (domestic) or 1-412-858-5206 (international) 10 minutes prior to the start time and reference the Warrior Met Coal conference call. A.
Black Bear Value Fund, LP (the “Fund”) returned -10.3% in September, +2.5% in the quarter and +4.1% YTD. Builders FirstSource declined approximately 36% during the third quarter and was down roughly 45% year to date as housing weakness continued to pressure results. Core Natural Resources appreciated approximately 8% during the third quarter and was down roughly 2% year to date, including dividends.
Warrior Met Coal now drives earnings growth through volume and cost reductions, not just coking coal price leverage. Blue Creek Mine's early ramp added a second product line, boosting Q2 sales to a record 3.7M short tons and lowering unit costs to $92.53/ton. HCC's forward multiples compress sharply due to contracted volume growth, offering superior visibility versus price-driven peers and supporting valuation.